Bookmark and Share
BioAssay: AID 588705

Luminescence-based toxicity of MDA231 Breast Cancer cells_2058-09_Inhibitor_Dose_DryPowder_Activity

Assay Overview: The objective of the experiments in this proposal is to identify chemical compounds that can selectively kill breast cancer. The human breast cancer cell line, MDA231, was used. Compounds are added to cells and are incubated ~72 hours. Cell viability was measured using CellTiter-Glo and luminescence is measured. The chemical compounds that selectively kill CSCs and kill human breast cancer cell lines would be promising new drug candidates for anti-cancer therapy. Compounds would also serve as useful probes to study CSC biology, which are currently lacking. ..more
_
   
 Tested Compounds
 Tested Compounds
All(7)
 
 
Active(6)
 
 
Inactive(1)
 
 
 Tested Substances
 Tested Substances
All(7)
 
 
Active(6)
 
 
Inactive(1)
 
 
 Related BioAssays
 Related BioAssays
AID: 588705
Data Source: Broad Institute (2058-09_Inhibitor_Dose_DryPowder_Activity)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network, Assay Provider
Deposit Date: 2011-10-26
Hold-until Date: 2012-01-28
Modify Date: 2012-01-28

Data Table ( Complete ):           Active    All
BioActive Compounds: 6
Depositor Specified Assays
AIDNameTypeComment
2721Summary of Broad Institute MLPCN Breast Cancer Stem Cell Toxicity ProjectsummarySummary of Broad Institute MLPCN Breast Cancer Stem Cell Toxicity Project
Description:
Keywords: Breast Cancer Stem Cells, MDA231

Assay Overview: The objective of the experiments in this proposal is to identify chemical compounds that can selectively kill breast cancer. The human breast cancer cell line, MDA231, was used. Compounds are added to cells and are incubated ~72 hours. Cell viability was measured using CellTiter-Glo and luminescence is measured. The chemical compounds that selectively kill CSCs and kill human breast cancer cell lines would be promising new drug candidates for anti-cancer therapy. Compounds would also serve as useful probes to study CSC biology, which are currently lacking.

Expected Outcome: Compounds significantly suppressing luminescence, and therefore toxic to MDA231 cells will be identified as hits in the screen.
Protocol

Protocol:
CSC media complete media + serum= Propagation media

Using already filtered/sterile components, add:

440 ml DMEM (Cellgro 10-013-CM)
50 ml FBS (HyClone SH30071.03)
5 ml Pen/Strep
5 ml Glutamax-1 (Invitrogen 35050-061)
700ul 50 uM Hydrocortisone (Sigma H6909)
600 ul 10mg/ml Insulin (Sigma I9278)
500 ul 50 mg/ml Gentamicin (Sigma G1397)
250 ul 25 mg/ml Plasmocin (Invivogen ant-mpt)
50 ul 100 ug/ml EGF (Sigma E9644) resuspended in 2% serum/PBS
+
500 ml MEGM Complete Medium (Lonza CC-3051) or MEGM Bullet Kit with components CC-3150
1 ml BPE (Lonza CC-4009)
____________________
Makes 1 liter


CSC media complete media - serum= Screening media

Using already filtered/sterile components, add:

490 ml DMEM (Cellgro 10-013-CM)
5 ml Pen/Strep
5 ml Glutamax-1 (Invitrogen 35050-061)
700ul 50 uM Hydrocortisone (Sigma H6909)
600 ul 10mg/ml Insulin (Sigma I9278)
500 ul 50 mg/ml Gentamicin (Sigma G1397)
250 ul 25 mg/ml Plasmocin (Invivogen ant-mpt)
50 ul 100 ug/ml EGF (Sigma E9644) resuspended in 2% serum/PBS
+
500 ml MEGM Complete Medium (Lonza CC-3051) or MEGM Bullet Kit with components CC-3150
1 ml BPE (Lonza CC-4009)
____________________
Makes 1 liter



MDA2310 Cells were propagated in Propagation media. For experiments, cells were plated using Screening media.

were seeded in 40 ul of Screening medium containing 1000 cells per well into white 384-well opaque-bottom plates (Nunc, Rochester, NY) using an automated plate filler (Bio-Tek uFiller; Winsooki, VT). At 24 hr, 100 nL of compound solutions were pin transferred from stock 384-well plates into the 384-well assay plates containing cells, resulting in 0.010-032 uM final concentration. Cells were incubated for 72 hrs.

HMLE_shEcad lines were each screened in two replicates. Two kinds of negative control wells were employed for normalization: multiple DMSO-only control wells were present on each compound assay plate screened. CellTiter-Glo Reagent (Promega) was added 3 days after compound addition (20 ul/well). Luminescence signal was measured with an automated plate reader (Perkin-Elmer Envision 1).




Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1AC50_uM*the concentration whereupon activity reaches 50% of the maximumFloatμM

* Activity Concentration.
Additional Information
Grant Number: 1R03MH089663-01

Data Table (Concise)
PageFrom: